TerminatedNCT04951609
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy
This study evaluates the safety of Seltorexant for people with depression.
Medication studyAges 12–17Multiple countries
Understand this study
What is this study about?
This study evaluates the safety of Seltorexant for people with depression.
Who could participate?
Listed age limits: 12 years to 17 years.
- Listed locations
- Phoenix and 22 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 2, 2021
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 31
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States, United Kingdom, Italy, ...
- Age range
- From 12 Years to 17 Years
- Official registry ID
- NCT04951609
- Official title
Show the full official title
A Short-term Exploratory Study to Evaluate Safety, Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to SSRI Monotherapy and Psychotherapy
Recruitment & locations
TerminatedPhoenix, United States · Anaheim, United States · San Diego, United States
17 more locations
- New Haven, United States
- Gainesville, United States
- Orlando, United States
- Naperville, United States
- Cincinnati, United States
- West Chester, United States
- Nashville, United States
- Dallas, United States
- The Woodlands, United States
- Genova, Italy
- Roma, Italy
- Esplugues de Llobregat, Spain
- Madrid, Spain
- Majadahonda, Spain
- Sabadell, Spain
- London, United Kingdom
- Oxford, United Kingdom
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety of Seltorexant for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Does this study involve medication?
Yes. The study involves medication, including Seltorexant and Placebo.
Who can participate?
Listed age limits: 12 years to 17 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Depression in bipolarity
A 12-week, proof of concept prospective, randomized, double blind, phase 2a study to compare safety and efficacy of masitinib to placebo in the treatment of mood disorders in patients with antidepr...